chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I was taking a shower the night of 04/28/21 and I had a bad pain in my right leg. It felt like it could be a blood clot. The area was swollen and I was in a lot of pain. My blood pressure started getting high and it kept going up. On the way to the hospital, I started getting a headache and shortness of breath. I tried to elevate my leg on the way there. I took an aspirin. I had to sit in the waiting room for 2 1/2 hours and my pain in my leg and headache continued. Once I was taken back, they ran a few tests. I was told that my D-Dimer was elevated which indicates a blood clot. I was checked for a pulmonary embolism and that was negative. I was given a blood thinner because an ultrasound technician was not on duty. I went home at 4 am. I went back for an ultrasound the next day for my entire leg. Everything came back normal. The pain slowly went away.
I began to experience a tightening sensation in my throat about 5-10 minutes after the vaccine injection. I was worried about getting stuck at the pharmacy or forced to visit the hospital so I went home, where my throat continued to constrict and my voice became hoarse. I called the pharmacy and they recommended Benadryl. I took one 25mg Benadryl (~5:00pm) which helped, but my throat began to tighten again about 1 hour later so I took another Benadryl (~6:00pm), and then 1 more Benadryl 3 hours later before I went to bed at 10pm. This resolved the tightening in my throat and hoarse voice. This reaction was similar to the anaphylactic reaction I experience when I?m exposed to peanuts.  It would have been smart to go to the hospital, but I did not want to incur the cost.
Extremely dizzy, nausea, tiredness, loss of appetite, pale color, no fever but very uncomfortable/"clammy". Had vaccine (3rd of series) on June 5 and symptoms began the following day. Are still present today, but doing better.
Ocular shingles V1 and V2 distribution., headache, malaise  x 10 days (still present)  Rx with ASA, Acyclovir, and Prednisone
1320- Patient reports that she gets dizzy with injections. Vasalvagal precautions advised. Patient ambulated to triage room and was supine for injection 1325- Patient reporting dizziness. Pt brought to triage room to help interpret. BP 107/77, HR 66, O2 sat 99%. Patient denies nausea, headache or other symptoms. 1329- BP 107/71, HR 74; O2 sat 99%. Patient offered water and sat up and took some sips of water. Denies dizziness while sitting up. 1333- BP 105/71; HR 62; O2 sat 100%.. Patient HOB raised 30 degrees. Denies dizziness, SOB, or other symptoms. Encouraged patient to drink water. Offered crackers, declined. 1335- Patient HOB raised to 90 degrees. BP 108/75; HR77, O2 sat 100%. Patient denies dizziness. Advised patient to discuss dizziness with providers prior to injection. Patient stated understanding. Patient stating she feels 'much better'.  1338- Legs dangling- BP 110/74; HR 65; O2 sat 100%. Denies dizziness. Patient stood without difficulty and ambulated to chair, gait steady, denies dizziness. 1345- Patient ambulated to private vehicle, gait steady, denies dizziness.
Patient experienced redness on the injection arm which comes and goes away. it started about 3 days after she received the vaccine and currently seems to be going down but still there on the 11th day
Day after receiving H1N1 felt sick to stomach, could not eat, had dry heaves. Symptoms resolved 2 days later.
Right leg pain. Especially in the morning. Using Salonpas which helps for a little while.
26 min after injection c/o fatigue and off and on episodes of diaphoresis ever since.
purple burst/point in the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE BRUISING (purple burst/point in the injection site) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced VACCINATION SITE BRUISING (purple burst/point in the injection site). At the time of the report, VACCINATION SITE BRUISING (purple burst/point in the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication details was reported.
pt states that the day after she got the covid vax she woke up with a hard lump around the injection site that developed severe itchiness.  Later in the day she noticed raised bumps like pimples on the lump that is around the injection site.  She showered and then used a Benadryl spray.  She still has the itchy rash today 3/3/2021 as well as some post nasal drip and sore throat.
Swelling and Soreness under arm/armpit. The swelling starting going down after day 3-4. On day 6, I woke up with bruising under arm/side of breast.
THE CUSTOMER HAS THE FOLLOWING SYMPTOMS POST VACCINATION; 1.Numbness in upper and lower extremities 2.Temporary "grip" issue on her fingers (unable to hold something) 3.Twitching in fingers 4. Arthritis in fingers post vaccination per customer
This spontaneous report as received from a Licensed Practical Nurse refers to an unspecified amount of patients of unknown age and gender. On an unkonwn dates the patient were vaccinated with doses of GARDASIL that underwent temperature excursions. On an unknown dates, unspecified amount of patients developed 'localized reactions' at the injection site after GARDASIL. The patients did not seek medical attention. No treatment was given for the events. The outcome of 'localized reactions' at the injection site was unknown. Relatedness between 'localized reactions' at the injection site and GARDASIL was not reported. This is one of several reports from the same source. Additional information has been requested.
Pt recvd 3 doses of Engerix-B 4JAN90, 5FEB90 & 6JUN90 & AUG91 titers tested & it was discovered that the pt did not convert antibody;
Low grade fever/fatigue the evening of the 18th. Complained of arm/armpit pain throughout the night and at 2am had muscle cramping/spasms that lasted a few minutes before resolving.
COVID+ 12/2/2022.  Vaccination status - moderna x4 + Moderna BIVALENT BRIEF OVERVIEW:  Admission Date: 12/2/2022 Discharge Date: Dec 5, 2022 Discharge Disposition:  home or self care   Active Issues Requiring Follow-up:   COVID pneumonia Bacterial pneumonia - Ceftin for 1 more day - isolate as able - Mask in public for next 5 days - Can discuss Paxlovid with PCP if desired - f/u blood cultures  Esophagitis Superficial gastric ulcers Hiatal hernia - PPI BID x8 weeks then daily - f/u PRN with GI - Limit NSAIDs - GERD lifestyle precautions - f/u biopsies - negative  HTN - Home meds resumed - Consider increasing doses if needed DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Hypoxia Coffee ground emesis Community acquired pneumonia, unspecified laterality COVID-19 virus infection Pneumonia due to COVID-19 virus   HOSPITAL COURSE: The patient is a 78 y.o. male with PMHx of HTN, hearing loss with cochlear implant, CKD3, HLD, anxiety, prostate cancer, insomnia who presented to the ED with complaints of fever, cough and coffee ground emesis. He developed a fever and tested positive for COVID-19. He subsequently developed nausea with some coffee ground emesis along with productive cough and dyspnea. In the ER CXR with patchy airspace disease suggesting right basilar pneumonia. He was started on abx and admitted to medicine for pneumonia.   He was quickly weaned off supplemental oxygen. He continued on abx for bacterial pneumonia and was discharged with 1 more dose of Ceftin. When he presented he had significant coffee ground emesis and requested GI consult. Hemoglobin with drastic decrease from 14 to 10 and GI evaluated. EGD done on 12/4 with esophagitis, gastric ulcers, and hiatal hernia. Hemoglobin remained stable. Given his clinical stability he was discharged home on 12/5/22.  CONSULTS / RECOMMENDATION: GI - EGD done, see above for other findings/recs
pt recv vax 23SEP97 & the next day pt exp malaise, nausea & an inj site rxn consisting of redness, warmth & induration;no angioedema, tightening of the chest, rash or swelling noted;
Patient received FLUVIRIN vaccine on 9/9/10 around 11:30 A.M. She states that she developed hives all over her body about 2 hour later. Patient took BENADRYL by mouth before going to bed that day, and was doing better the next day. I was notified of the situation by patient today (9/10/10) at 7:00 P.M.
My left arm has hurt ever since getting the shot. It is painful to lay on. Also, I am having pain when raising my arm that is limiting movement.
I had a bad eczema type outbreak covering my face, chest, back, thighs, arms, and scalp.  It's been going on for about three months now.  It's bad on my scalp and it's making my hair fall out.
half hour after I received the vaccine. I started to have facial tingling . It lasted about an hours. I also experienced headache chills and diarrhea the first forty eight hours. For a week I had muscle soreness and fatigue . i am also pregnant with EDD: 4/16/21
Contracted COVID in April before they could receive the 2nd dose; Contracted COVID in April before they could receive the 2nd dose; This is a spontaneous report from a contactable pharmacist. A 78-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE: Solution for injection; Batch/Lot number: unknown), dose 1 via an unspecified route of administration on as dose 1, for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient received her first dose of the Pfizer COVID Vaccine on 26Mar2021. She and her husband (who also received the vaccine) contracted COVID on an unspecified date of Apr2021 before they could receive the 2nd dose and were hospitalized for 2 weeks. The husband passed away, while the patient recovered from a severe (not mild) COVID infection. She was asking if she could get the 2nd dose and when should she receive the 2nd dose. On an unspecified date of Apr2021 patient underwent lab tests and procedures which included sars-cov-2 test: contracted covid. The outcome of the event was recovered on an unspecified date in 2021.  Information about batch/lot number has been requested.; Sender's Comments: Based on the reported information ,a causal relationship between the events "Drug Ineffective" and "Covid-19" and suspected drug cannot be excluded.
left wrist with swelling erythema; left wrist with swelling erythema; raised rash over painful joint; Joint pain through out body but worse in left wrist the following day/raised rash over painful joint; dose number=3; This is a spontaneous report from a contactable other health care professional.  A 41-years-old non-pregnant female patient received booster dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: FF8839, Expiry date: not reported), via an unspecified route of administration, administered in left arm on 06Oct2021 (Age at vaccination: 41 years old) as dose 3 (booster), single for covid-19 immunization at a hospital. Patient's medical history and concomitant medications were not reported. Patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EJ1685, Expiry date: not reported), via an unspecified route of administration, administered in left arm on 05Jan2021 (Age at vaccination: 40 years old) as dose 1, single for covid-19 immunization and received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EL3248, Expiry date: not reported), via an unspecified route of administration, administered in right arm on 26Jan2021 (Age at vaccination: 40 years old) as dose 2, single for covid-19 immunization. Patient did not take any vaccine in four weeks and any other medications in two weeks, patient did not get covid prior vaccination and did not get covid tested post vaccination and there no known allergies. On 06Oct2021, patient took dose number 3 (booster). On 07Oct2021, following day of vaccination, patient experienced joint pain throughout body but worse in left wrist. By 08Oct2021 am left wrist with swelling erythema and raised rash over painful joint. Patient did not take any treatment for adverse events. Outcome of events was recovering.  Follow-up attempts are completed. No further information is expected.
Initially Sudden uncontrollable tremors that last for over an hour with high blood pressure.(168/118)No warning signs. Many multiple episodes throughout the day only lasting a minute or less. Very tired, some chest tightness on and off throughout the day.
vaccination was not entirely thawed to room temp; This spontaneous case was reported by a physician and describes the occurrence of PRODUCT STORAGE ERROR (vaccination was not entirely thawed to room temp) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No relevant medical history).    On 18-Jan-2021 at 8:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021 at 8:00 AM, the patient experienced PRODUCT STORAGE ERROR (vaccination was not entirely thawed to room temp). On 18-Jan-2021 at 8:00 AM, PRODUCT STORAGE ERROR (vaccination was not entirely thawed to room temp) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided/unknown by the reporter. Treatment information was not provided/unknown.
Information has been received from a physician concerning a female who was vaccinated with a second dose of Gardasil.  Subsequently, the patient experienced an adverse event.  The physician did not elaborate on the specific of the adverse event.  Additional information has been requested.
Pt states about 7 days  after having the vaccine she developed weakness in her left leg, she was able to ambulate but was limping and was unable to put her full weight on her left foot, states 3 weeks after the vaccines she developed weakness radiated up into her left arm and shoulder, pt states symptoms have improved but not completely resolved,
swelling, warmth to the touch, and hardness at the injection site; swelling, warmth to the touch, and hardness at the injection site; swelling, warmth to the touch, and hardness at the injection site; Initial information received on 08-Aug-2022 regarding an unsolicited valid  non-serious case received from a physician.  This case involves a 5 years old and unknown gender patient who had swelling, warmth to the touch, and hardness at the injection site after receiving vaccine DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL].  The patient's past medical history, medical treatment(s), concomitant medication, vaccination(s) and family history were not provided.   On an unknown date, the patient received a 0.5ml dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE Suspension for injection (strength, lot number and expiry date was unknown) via unknown route in unknown administration site for immunization.  On an unknown date the patient developed a non-serious  event of swelling, warmth to the touch, and hardness at the injection site (vaccination site induration, vaccination site warmth and vaccination site swelling) (latency: unknown) following the administration of DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE.  Action taken :not applicable.  It was not reported if the patient received a corrective treatment for the events   Outcome: Unknown for all events.; Sender's Comments:  SanofiPVPortal20220809000954:PORTAL ID SanofiPVPortal20220811000466:PORTAL ID
Itching rash on back of knees, spread to left of trunk. Feeling "worn out". Nasal drainage. Better 10/20/2015.
1:19 @ 4 opm - nausea, dizzy, numbness , fatigue, increased blood pressure  Heart racing Went to hospital  as l 1/19 @ 8 Pm went to ED , EKG and blood work done for heart all were negative
The day after the vaccine was administered I became woozy and lathargic, really fatigued. This lasted about a day and then I returned to normal.
This spontaneous report was received from a physician via company representative, referring to a female patient of unknown age. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On 09-JUN-2017, the patient was vaccinated with PNEUMOVAX 23 injection, lot # N029303 and expiration date 21-APR-2019, for prophylaxis (dose, route of administration and anatomical location were not reported). On an unknown date following the administration, the patient developed cellulitis. It was unknown by the reporter if the patient sought medical attention, if treatment was given for the adverse events or if lab diagnostics or studies were performed. The outcome of the event cellulitis and the causal relationship between the event and therapy with PNEUMOVAX 23 were not reported. Upon internal review, cellulitis was considered to be medically significant. This is one of several cases from the same reporter.; Sender's Comments: US-009507513-1802USA001892: US-009507513-1802USA002516:
Extreme dizziness appears one week after first dose of vaccine and has not gone away yet extremely hard to focus and do daily tasks
CHILLS; RASH; FEVER OF 102; HEADACHE; FATIGUE; NAUSEA; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number Unk) dose was not reported, administered on 27-MAR-2021 16:00 on left arm for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 28-MAR-2021, the subject experienced chills. On 28-MAR-2021, the subject experienced rash. On 28-MAR-2021, the subject experienced fever of 102. On 28-MAR-2021, the subject experienced headache. On 28-MAR-2021, the subject experienced fatigue. On 28-MAR-2021, the subject experienced nausea. Laboratory data included: Body temperature (NR: not provided) 102 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the chills, fever of 102, headache, fatigue, nausea and rash was not reported. This report was non-serious.
Case previously recorded as MA2009-4546. Initial case report received from a nurse, on 18 NOV 2009. A 4 month-old female patient was vaccinated with 0.5 ml of FLUVIRIN 2009/2010 (batch no. 1021261P1A) i.m. on 17 NOV 2009, an off-label indication. No adverse event was reported. Reference no: NA09-008426.
Failure of the Shingrix vaccine with the patient/suspected vaccination failure; Experienced a rash on one testicle and buttocks and the PA was confident it was shingles; rash on one testicle; Rash related to the vaccine / rash on one testicle and buttocks; This case was reported by a other health professional via sales rep and described the occurrence of suspected vaccination failure in a 85-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. In October 2019, less than 2 years after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, genital rash and rash. On an unknown date, the outcome of the vaccination failure, shingles, genital rash and rash were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix. The reporter considered the genital rash and rash to be related to Shingrix and Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient experienced rash related to the vaccine. It was reported that it was a failure of the Shingrix with the patient. The patient received both the doses of Shingrix and experienced a rash on one testicle and buttocks and the reporter was confident it was shingles. The reporter consented to follow up. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset for the event and laboratory test confirmation were unknown. This case is 1 of the 4 cases reported by the same reporter.
Body aches; Fatigue; Sore throat; Congestion; 100.2 degree fever; Cough; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er2613), via an unspecified route of administration in the left arm on 25Mar2021 at 18:00 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Medical history included hypertension. The patient did not received any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 17:00, the patient experienced body aches, fatigue, sore throat, congestion, 100.2 degree fever and cough. On 31Mar2021, the patient underwent lab test included body temperature 100.2 degree. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events body aches, fatigue, sore throat, congestion,100.2-degree fever and cough were not recovered at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Rash to face and neck, mild headache. Benadryl 25 mg PO, PRN. Resolved 5/21/03.
2nd dose hasn't been given after 8 yrs of the original dose, no adverse event; Initial information received on 07-Oct-2019 regarding an unsolicited valid non-serious case received from a consumer/non health care professional.  This case involves a 13 years old female patient for whom it was reported that 2nd dose hasn't been given after 8 yrs of the original dose while she received vaccine DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT [TENIVAC] via unknown route and site of administration, on an unknown date.  The patient's past medical history, medical treatments, and family history were not provided. The patient had received a first dose of Tenivac in past. It was a case of actual medicaiton error due to inappropriate schedule of product administration.  The reporter was not sure if the patient was going to be administered Adacel or Tenivac but she believed that it was not being administered the way the package insert states. Caller states that the insert states that the 2nd dose has not been given after 8 yrs of the original dose. The patient was undergoing catchup vaccination, and the stated officials are saying the interval between the first and second dose of Td or Tdap is 4 weeks apart, can they administer it sooner than the interval listed in the PI.  At the time of reporting, no adverse event was reported  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error  Information on batch number was requested.